FEMASYS INC — SEC Form D Filing
FEMASYS INC filed an SEC Form D on August 20, 2026, reporting $30.00M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 20, 2026
- Amount reported
- $30.00M
- Round stage
- Series B+
- Industry
- Medical Devices
- Website
- https://femasys.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Women face a fertility crisis where existing IVF treatments are often too expensive, invasive, and inaccessible. Additionally, many women seeking permanent contraception desire non-surgical alternatives.
Solution
Femasys develops office-based, minimally invasive solutions for women's reproductive healthcare, including FemaSeed for earlier fertility treatment and FemBloc for non-surgical permanent birth control.
Why now
The increasing cost and invasiveness of traditional fertility treatments like IVF, coupled with a growing demand for less invasive and more accessible women's health solutions, create a timely market for Femasys's products.
Verdict
Investors saw a clear path to commercialization for a focused medical device play addressing well-understood women's health needs. This cleared because it offered a less invasive, office-based solution for common reproductive issues, not because it promised a revolutionary new treatment paradigm. The implicit bet was on adoption by existing physician networks and favorable reimbursement codes, rather than creating new markets or patient behaviors. Upside was limited by the need for clinical validation, regulatory hurdles, and physician training, common for medical devices.
Source: SEC EDGAR Form D filing